CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results